Cephradine Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable, model CRD-PG/TCGI-01, is a first-generation cephalosporin active pharmaceutical ingredient supplied for immediate-release tablets, hard gelatin capsules, dry granules for oral suspension, and injectable formulations. The molecule is (6R,7R)-7-[(R)-2-amino-2-(1,4-cyclohexadien-1-yl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, assigned CAS 38821-53-3, molecular formula C₁₆H₁₉N₃O₄S, and anhydrous molecular weight 349.41 g/mol. The commercial product is the monohydrate; water content is controlled at 4.0–6.5% by Karl Fischer titration. The monohydrate crystal form is verified by X-ray powder diffraction and infrared absorption against a current reference standard.

The model designation CRD-PG/TCGI-01 covers a single API grade aligned with both oral and injectable route requirements. This harmonization is deliberate: a separate injectable-only grade would carry the same synthesis and crystallization steps but with a different milling and final filtration train, whereas a multi-route grade simplifies regulatory filing while retaining injectable compliance. The material is manufactured under ICH Q7 and is supported by a US Type II drug master file or a Certificate of Suitability to the European Pharmacopoeia where required. Each batch is released against a certificate of analysis that includes identity, assay, related substances, residual solvents, elemental impurities, water content, specific optical rotation, and pH. For the injectable route, additional lot-specific data include bacterial endotoxin, microbial enumeration, and subvisible particulate matter after reconstitution into water for injection.

Which specification controls become route-limiting when one grade serves tablets, capsules, granules, and injection?

In a harmonized multi-route grade, the injectable presentation imposes the tightest limits for microbial quality. A bacterial endotoxin release limit of ≤ 0.10 EU/mg is applied because parenteral dosing must meet the endotoxin budget described in USP <85>. Oral-only cephalosporin APIs may be released with higher bioburden, but such material cannot be retrospectively qualified for injection. Similarly, the injectable route requires that the final reconstituted solution meet USP <787> or USP <788> for subvisible particulate matter; therefore the API is screened through a 75 µm sieve and may be jet-milled to D90 ≤ 100 µm for injection-grade orders. The oral grades are coarser; a particle-size specification of D90 ≤ 250 µm is typical for tablet and capsule processing. In both cases, particle size is measured by laser diffraction following ISO 13320, with the dispersion medium selected to avoid dissolution.

The pH of a 1% aqueous suspension is controlled because it influences dissolution rate and solution clarity during injectable compounding. The related-substances method uses an octadecylsilyl column with a phosphate buffer–acetonitrile mobile phase; peaks are quantified at 254 nm or 210 nm depending on the specific monograph. Impurity profiling includes process impurities from the synthesis route and degradation products from beta-lactam hydrolysis. The limit for any individual unknown impurity is set at 0.10%, while the total impurity limit is 1.0%; a tighter total limit may be applied for injectable submissions where stability data show hydrolytic product accumulation.

Residual solvent monitoring follows the same multi-route logic. Because the API may be used in injectable formulations, Class 1 solvents are excluded and Class 2 solvents are controlled to the lower of oral and parenteral permitted daily exposures under ICH Q3C. If a Class 2 solvent appears above the limit, the batch is reworked or rejected before release. Elemental impurities are controlled under ICH Q3D using an inductively coupled plasma mass spectrometry method; oral and parenteral permitted daily exposure limits are applied depending on the final route.

Solid oral processing with this API becomes operationally challenging above 50–60% w/w drug load. Direct compression is feasible when the particle-size distribution is controlled to D10 ≥ 20 µm, D50 70–120 µm, and D90 ≤ 250 µm. Under these conditions, the powder blend typically exhibits a bulk density of 0.35–0.50 g/mL and a tapped density of 0.50–0.70 g/mL, yielding a Hausner ratio below 1.35. On a rotary tablet press operating at 60–80 rpm with 9 mm round concave tooling, tablets can be compressed to 6–10 kp hardness. If compression force is increased to control friability, capping may occur above 20 kN because the crystalline powder exhibits low plastic deformation and high elastic recovery. A common corrective action is to add microcrystalline cellulose and croscarmellose sodium, or to switch to dry granulation by roller compaction.

Wet granulation is used for high-dose tablets and dry granules for oral suspension. A high-shear granulator with a chopper speed of 1500 rpm and an impeller speed of 250 rpm can provide adequate binder distribution, but the wet mass temperature must remain below 40°C to minimize beta-lactam hydrolysis. After fluid-bed drying to ≤ 2.0% w/w moisture, the granules are milled through a 0.8 mm screen and lubricated with magnesium stearate. The resulting granules should have a Carr index below 25% to avoid weight fluctuation on high-speed capsule fillers. Dosator-type capsule machines require a uniform granule density; free-flowing API with a wide particle-size distribution can cause fill weight variability greater than 3% RSD.

For capsule filling, the API is often blended directly with lactose monohydrate and a low-dose disintegrant because cephradine itself is moderately cohesive. Electrostatic charge build-up in low-humidity environments, typically below 30% RH, can cause powder adhesion to the dosing disc and increase fill weight failure. Humidity-controlled rooms at 40–50% RH are therefore used. Hard gelatin capsule shells require the fill material to have a moisture content ≤ 5% to prevent shell brittleness and cross-linking. If a hydroxypropyl methylcellulose shell is selected for stability reasons, the moisture specification is often adjusted to ≤ 8%, but release-rate equivalence must be reconfirmed because HPMC capsules can show different dissolution performance in acidic media.

Dissolution testing for immediate-release cephradine tablets and capsules is conducted per USP <711> using 900 mL of 0.1 N HCl at 37°C with paddle speed 50 rpm. A typical release acceptance criterion is ≥ 80% dissolved in 30 min, but tighter in-house limits may be applied to support bioequivalence. Granules for oral suspension are first reconstituted with water to the labeled concentration and then analyzed without further sample preparation. Because cephradine has high aqueous solubility relative to dose, dissolution failure is usually a formulation or manufacturing problem rather than an intrinsic solubility problem.

When sterile powder filling requires additional depyrogenation and compatibility limits

Injectable cephradine is manufactured from the same API molecule but with route-specific controls. The API is not supplied as sterile; the dosage-form manufacturer must dissolve the powder in water for injection, reduce endotoxin burden if required, and fill into Type I glass vials under Grade A conditions. Depyrogenation may be achieved by activated carbon treatment, anion-exchange adsorption, or filtration through a positively charged membrane; the sterile filtration step is not intended for endotoxin removal. A typical manufacturing procedure uses a 0.22 µm polyethersulfone filter, but the filter membrane must be qualified for cephradine binding because cephalosporins can bind to some nylon membranes. The solution pH is adjusted to 5.0–6.5 with dilute sodium hydroxide or hydrochloric acid; this range balances chemical stability of the beta-lactam ring with physiological compatibility.

The injectable route also changes the required stability data. Terminal sterilization is not universally applied because cephradine in aqueous solution degrades at elevated temperature; aseptic processing is therefore common. If terminal sterilization is used, the thermal cycle must be justified by degradation data showing total impurities do not exceed the injectable limit. The reconstituted solution should be used within the time validated in the product dossier; holding times in the literature are often limited to 24 h at 2–8°C, but the specific limit depends on the formulation and container closure. The API manufacturer does not assign this limit; the finished-product manufacturer establishes it under ICH Q1A and regional requirements.

Compatibility limits are equally important. Cephradine is physically incompatible with aminoglycoside antibiotics such as gentamicin and amikacin in the same infusion container. If co-administration is required, separate infusion lines and staggered administration are used. The product should not be mixed with calcium-containing intravenous fluids unless compatibility has been demonstrated, and the solution should be protected from excessive light during prolonged infusion. Published data for some specific container-closure combinations is limited; therefore the finished-product manufacturer performs in-use stability studies per EMA Guideline on the Stability of Sterile Parenteral Products or equivalent regional guidance.

When compared with cephalexin, cephradine shares a first-generation cephalosporin spectrum and oral absorption above 90% in fasted adults, but the two APIs differ in regulatory status, hydrate form, and route availability. Cephalexin is available mainly as oral tablets, capsules, and suspension; cephradine has oral and injectable presentations in certain markets. Cefadroxil has a longer elimination half-life and can be dosed once or twice daily. Cefazolin is an injectable first-generation cephalosporin typically used for perioperative prophylaxis, but it has negligible oral absorption. The table below summarizes key comparative properties.

This product difference matters in manufacturing because cephradine can be considered when a single active pharmaceutical ingredient is required for both oral and parenteral formulations. The same hydrate and particle-size grade can be qualified for both route families if the injectable-specific limits are met from the start. By contrast, cephalexin sourced for oral use is rarely tested for the endotoxin and particulate controls needed for injection. Switching a formulation from cephalexin to cephradine requires new bioequivalence studies because dissolution, permeability, and drug-release profiles may differ despite the similar spectrum.

The activity profile of cephradine is not broad enough for resistant organisms. It is not active against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, or Enterococcus spp. It is also hydrolyzed by extended-spectrum beta-lactamases and AmpC chromosomal beta-lactamases. Therefore the choice of cephradine as an API is restricted to susceptible infections and cannot be justified by manufacturing convenience alone. For empirical therapy where resistant Gram-negative organisms are suspected, a cephalosporin with greater beta-lactamase stability or a non-beta-lactam agent is required.

The API is packaged in double low-density polyethylene bags enclosed in a fiber drum with desiccant. Storage conditions are controlled at 25°C/60% RH with excursions allowed according to ICH Q1A for Zone II. The retest period is established from stability data; typical API retest periods for dry cephalosporins are 24–36 months when stored in the unopened original container. Once opened, the drum should be resealed with desiccant because hydration of the monohydrate can change water content and compression properties. Bulk handling equipment must be dedicated or thoroughly cleaned because cephalosporin APIs are beta-lactam antibiotics and cross-contamination with non-beta-lactam products must be prevented. Cleaning validation uses surface swab limits of 1–10 ppm or a health-based exposure limit derived from the permitted daily exposure; the exact limit depends on the next product and regional guidance.

During transfer and sampling, the API should be protected from high humidity above 60% RH. If the powder is exposed to moisture, the water content may increase beyond 6.5% and the material may become sticky during milling or compression. Pre-drying at 40–50°C under vacuum is possible for oral grades, but the drying time must be short and the material re-equilibrated to avoid overdrying and amorphization. Overdrying can reduce water content below 4.0% and alter the hydrate form; this is detected by XRPD and may affect dissolution. Injectable-grade API should not be pre-dried without written authorization because uncontrolled thermal treatment may increase degradation products and endotoxin extraction is not improved by drying.